Outsourcing in Clinical Trials Southern California 201423-24 September 2014, La Jolla, CA
The OCT team would like to thank you for making the 2013 launch event such a huge success.
In September this year over 200 pharmaceutical, biotechnology and medical device professionals attended our first Outsourcing in Clinical Trials Southern California event to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges.
With a unique programme catering to 3 unique company types (biotech/pharma, virtual, medical device) content covered all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques. This year’s agenda boasted presentations, case studies, panel discussions and roundtables all presented and facilitated by a high calibre speaking faculty local to this industry hub.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout Southern California.
Outsourcing in Clinical Trials Southern California boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
Pfizer has released top-line results from two major Phase III trials from the Oral treatment Psoriasis Trials (OPT) Programme, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), of tofacitinib, the first in a new class of medicines, to treat pa…
Cubist Pharmaceuticals has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) for its investigational antibiotic, ceftolozane/tazobactam for the treatment of complicated urinary tract infections (cUTI) and complicated i…
US-based biopharmaceutical firm Questcor Pharmaceuticals has reported results from an investigator-initiated clinical trial evaluating the dosing and effectiveness of HP Acthar Gel (repository corticotropin) in 20 patients with nephrotic syndrome due…
US-based VentiRx Pharmaceuticals has announced the completion of patient enrollment in GOG-3003, a Phase II study of VTX-2337 in combination with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallo…
US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated locally …
Sweden-based Aprea, a Karolinska Development portfolio company, has started dosing patients in the Phase I/II clinical trial of APR-246 in combination with chemotherapy to treat ovarian cancer.